165 related articles for article (PubMed ID: 34554200)
1. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.
Aggarwal R; Rydzewski NR; Zhang L; Foye A; Kim W; Helzer KT; Bakhtiar H; Chang SL; Perry MD; Gleave M; Reiter RE; Huang J; Evans CP; Alumkal JJ; Lang JM; Yu M; Quigley DA; Sjöström M; Small EJ; Feng FY; Zhao SG
JAMA Oncol; 2021 Nov; 7(11):1644-1652. PubMed ID: 34554200
[TBL] [Abstract][Full Text] [Related]
2. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.
Zhao SG; Chang SL; Erho N; Yu M; Lehrer J; Alshalalfa M; Speers C; Cooperberg MR; Kim W; Ryan CJ; Den RB; Freedland SJ; Posadas E; Sandler H; Klein EA; Black P; Seiler R; Tomlins SA; Chinnaiyan AM; Jenkins RB; Davicioni E; Ross AE; Schaeffer EM; Nguyen PL; Carroll PR; Karnes RJ; Spratt DE; Feng FY
JAMA Oncol; 2017 Dec; 3(12):1663-1672. PubMed ID: 28494073
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.
Feng E; Rydzewski NR; Zhang M; Lundberg A; Bootsma M; Helzer KT; Lang JM; Aggarwal R; Small EJ; Quigley DA; Sjöström M; Zhao SG
Clin Cancer Res; 2022 Dec; 28(24):5396-5404. PubMed ID: 36260524
[TBL] [Abstract][Full Text] [Related]
4. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
Feng FY; Thomas S; Saad F; Gormley M; Yu MK; Ricci DS; Rooney B; Brookman-May S; McCarthy S; Olmos D; Chowdhury S; Hadaschik B; Liu Y; Davicioni E; Smith MR; Small EJ
JAMA Oncol; 2021 Jul; 7(7):1005-1014. PubMed ID: 34081076
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.
Coleman IM; DeSarkar N; Morrissey C; Xin L; Roudier MP; Sayar E; Li D; Corey E; Haffner MC; Nelson PS
Clin Cancer Res; 2022 Jul; 28(14):3127-3140. PubMed ID: 35552660
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
Aggarwal R; Huang J; Alumkal JJ; Zhang L; Feng FY; Thomas GV; Weinstein AS; Friedl V; Zhang C; Witte ON; Lloyd P; Gleave M; Evans CP; Youngren J; Beer TM; Rettig M; Wong CK; True L; Foye A; Playdle D; Ryan CJ; Lara P; Chi KN; Uzunangelov V; Sokolov A; Newton Y; Beltran H; Demichelis F; Rubin MA; Stuart JM; Small EJ
J Clin Oncol; 2018 Aug; 36(24):2492-2503. PubMed ID: 29985747
[TBL] [Abstract][Full Text] [Related]
7. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a
Spratt DE; Alshalalfa M; Fishbane N; Weiner AB; Mehra R; Mahal BA; Lehrer J; Liu Y; Zhao SG; Speers C; Morgan TM; Dicker AP; Freedland SJ; Karnes RJ; Weinmann S; Davicioni E; Ross AE; Den RB; Nguyen PL; Feng FY; Lotan TL; Chinnaiyan AM; Schaeffer EM
Clin Cancer Res; 2019 Nov; 25(22):6721-6730. PubMed ID: 31515456
[TBL] [Abstract][Full Text] [Related]
8. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Weiner AB; Liu Y; Hakansson A; Zhao X; Proudfoot JA; Ho J; Zhang JH; Li EV; Karnes RJ; Den RB; Kishan AU; Reiter RE; Hamid AA; Ross AE; Tran PT; Davicioni E; Spratt DE; Attard G; Lotan TL; Lee Kiang Chua M; Sweeney CJ; Schaeffer EM
Cancer; 2023 Jul; 129(14):2169-2178. PubMed ID: 37060201
[TBL] [Abstract][Full Text] [Related]
9. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract][Full Text] [Related]
10. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
14. Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study.
Conteduca V; Wetterskog D; Castro E; Scarpi E; Romero-Laorden N; Gurioli G; Jayaram A; Lolli C; Schepisi G; Wingate A; Casadei C; Lozano R; Brighi N; Aragón IM; Marin-Aguilera M; Gonzalez-Billalabeitia E; Mellado B; Olmos D; Attard G; De Giorgi U
Eur J Cancer; 2021 Jul; 152():49-59. PubMed ID: 34077818
[TBL] [Abstract][Full Text] [Related]
15. Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.
Notohardjo JCL; Kuppen MCP; Westgeest HM; van Moorselaar RJA; Mehra N; Coenen JLLM; van Oort IM; de Vos AI; Vervenne WL; van den Bergh ACM; Aben KKH; Somford DM; Bergman AM; Uyl-de Groot CA; Gerritsen WR; van den Eertwegh AJM
Eur Urol Focus; 2021 Jul; 7(4):788-796. PubMed ID: 32362484
[TBL] [Abstract][Full Text] [Related]
16. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
[TBL] [Abstract][Full Text] [Related]
17. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
[TBL] [Abstract][Full Text] [Related]
18. The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis.
Liu RJ; Hu Q; Li SY; Mao WP; Xu B; Chen M
Technol Cancer Res Treat; 2021; 20():15330338211035260. PubMed ID: 34313171
[TBL] [Abstract][Full Text] [Related]
19. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.
Aggarwal R; Romero GR; Friedl V; Weinstein A; Foye A; Huang J; Feng F; Stuart JM; Small EJ
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):81-87. PubMed ID: 32286548
[TBL] [Abstract][Full Text] [Related]
20. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A; Hotte S; Tran B; North S; Taavitsainen S; Beja K; Vandekerkhove G; Ritch E; Warner E; Saad F; Iqbal N; Nykter M; Gleave ME; Wang Y; Annala M; Chi KN; Wyatt AW
Eur Urol; 2020 Dec; 78(6):834-844. PubMed ID: 32451180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
